Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

A rare syndrome linked to purple urine reveals surprising insights into bacterial colonisation, metabolism, and risks for ...

A northeast Portland neighborhood is grappling with a mystery man who leaves bottles of urine in their recycling bins, ...

The minimum investment in UTI Small Cap Fund Regular Growth is Rs ... Multi Commodity Exchange Of Ind, Blue Star & Avanti Feeds. The major sectors where the fund is invested are Chemical ...

A devastating 77-magnitude earthquake struck Myanmar unleashing energy equal to 334 atomic bombs Experts warn of lasting ...

Troy Casey doesn’t mind the taste, calling it “hair of the dog” — but several experts have shared warnings about his “direct biofeedback loop.” ...

The Global Nutraceuticals Market valued at $416 billion (2021), is expected to witness a growth rate of 8-9% in the next five ...

GSK has confirmed that Blujepa will be commercially available in the U.S. by the second half of 2025, providing a much-needed addition to the arsenal of treatments for UTIs. Implications for the ...